First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia

Background: In COVID-19, high levels of granulocyte macrophage-colony stimulating factor (GM-CSF) and inflammatory myeloid cells correlate with disease severity, cytokine storm, and respiratory failure. With this rationale, we used lenzilumab, an anti-human GM-CSF monoclonal antibody, to treat patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:medRxiv
Main Authors: Temesgen, Zelalem, Assi, Mariam, Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Varatharaj Palraj, Bharath Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310641/
https://ncbi.nlm.nih.gov/pubmed/32587983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.08.20125369
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados